Japan’s New 'Fast-Break Scheme' To Reduce Clinical Trial Burden For Medtech
Japan’s “fast-break scheme” is coming soon and will be the country’s fourth procedure for accelerating the approval of important medical devices.
You may also be interested in...
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.
Companies operating in New Zealand will have six months to transition to Medsafe’s updated code on good manufacturing practice.
Alexion is collecting more evidence to convince NICE that its anticoagulant reversal agent is also cost-effective for intracranial hemorrhage.